Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
about
Cardiovascular disease in adult survivors of childhood cancer.Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological studyManaging chemotherapy-related cardiotoxicity in survivors of childhood cancers.Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision AnalysisLong-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis.Systematic assessment of decision-analytic models for chronic myeloid leukemia.The role of hematopoietic stem cell transplantation in chronic myeloid leukemia.Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Performance of Sokal and Eutos Scores for Predicting Cytogenetic and Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients on Imatinib.Efficient synthesis of novel 3-aryl-5-(4-chloro-2-morpholinothiazol-5-yl)-4,5-dihydro-1H-pyrazoles and their antifungal activity alone and in combination with commercial antifungal agents.
P2860
Q34042984-66F51B84-648D-49A1-A2E5-8CDF5B885493Q34567058-5DC61D1F-C846-439F-B2A1-F6149912FEB3Q35562745-35965565-9E35-4EE0-8EC6-A695C839BD3AQ36263943-299461AB-71B3-48E6-9CBB-28F70B3EA916Q36400944-E82D0C7F-F05D-4C0B-A3A8-51BAAC219A68Q36650103-D7BB4722-EC55-4273-806B-253549349C3DQ37598156-21B17B6D-34A7-4F47-BE46-08B3F73DF3ADQ38175353-CED751D3-BABA-4517-A19E-0EA94B6D7681Q38392690-50A8FFE0-7432-4A3B-9A88-FC47D2F8A264Q44383576-64758C2A-930A-430C-8F28-D39D714EBE84Q53508619-7FE6EAD1-1283-4DBB-A076-DAA5FCFEAC71Q53840409-6D96156F-281E-4C1B-95C0-4878A63DE343
P2860
Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Dasatinib, nilotinib and stand ...... reviews and economic analyses.
@en
type
label
Dasatinib, nilotinib and stand ...... reviews and economic analyses.
@en
prefLabel
Dasatinib, nilotinib and stand ...... reviews and economic analyses.
@en
P2093
P50
P356
P1476
Dasatinib, nilotinib and stand ...... reviews and economic analyses
@en
P2093
L Crathorne
L Osipenko
M Venkatachalam
O Ukoumunne
R Anderson
T Jones-Hughes
P304
iii-iv, 1-277
P356
10.3310/HTA16420
P577
2012-01-01T00:00:00Z